ArticleFrontiers in immunology2026
Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Invasive fungal infections (IFI) remain a major therapeutic challenge due to limited antifungal options, emergence of multidrug-resistant (MDR) strains and high mortality rates. This has turned up the development of immune-based therapies to restore and/or enhance anti-fungal immune responses into a clinical priority. This is in line with the recent demonstration that antifungal activity of primary (cord blood-derived) NK cells can be potentiated by endowing them with a CD5-based second-generation chimeric antigen receptor (SRCD5CAR) targeting β-glucans, a constitutive and broadly distributed component of fungal cell walls. Building on this, we aimed at exploring whether the reported constitutive antifungal activity of leukemia-derived NK-92 cells can also be potentiated by engineering them for further potential use as a homogeneous and ready-to-use source of allogeneic cells for adoptive transfer therapy in IFI. Methods: NK-92 cells lentivirally transduced and selected for stable and high-level expression of the SRCD5CAR for further testing in in vitro fungal killing assays, as well as in an Results: SRCD5CAR-NK-92 cells showed superior antifungal activity than untransduced NK-92 cell counterparts. SRCD5CAR-NK-92 cells also exhibited superior activity against a MDR Discussion: Despite the patient ultimately succumbed due to progression of the underlying hematological malignancy, this represents first-in-human use of SRCD5CAR-NK-92 cells in the context of a severe MDR IFI. The results highlight its potential as a safe and off-the-shelf therapeutic strategy, while underscoring the need for further investigation on efficacy and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.